ALX ONCOLOGY HOLDINGS INC (ALXO): Submission of Matters to a Vote of Security Holders
ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001810182 false 0001810182 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
How this was made
The 30-second read
Why it matters
The disclosure confirms governance outcomes: two class II director elections, an advisory vote on executive compensation, and ratification of KPMG LLP as independent auditor for FY ending Dec. 31, 2026.
Market read
Confirms routine governance votes; no new clinical, financial, or strategic catalyst is disclosed.
What to watch
Traders should verify whether any separate, contemporaneous proxy/8-K items (e.g., contested election, auditor change, material agreements) exist; this specific item appears procedural.
Background
The SEC 8-K Item 5.07 summarizes matters submitted to a vote of security holders at ALX Oncology’s June 10, 2026 annual meeting.
Ticker impact
ALX Oncology filed an 8-K reporting June 10, 2026 annual meeting voting results, including election of directors and ratification of KPMG.
Likely limited near-term impact; any reaction would be sentiment/technical rather than fundamental.
The filing only reports director election, advisory say-on-pay, and auditor ratification—items that typically do not change cash flows or risk materially.
Market effects
Minimal; governance/auditor ratification does not alter biotech sector fundamentals.
Minimal; US-listed governance filing for a single issuer.
Minimal; no cross-border transaction or regulatory action mentioned.
Counterpoint
If the market had been pricing governance uncertainty, the confirmed director slate and auditor ratification could reduce overhang, but the filing provides no evidence of such a dispute.
Key entities
- issuerALX Oncology Holdings Inc.
Company filing the 8-K and reporting annual meeting voting results.
- auditorKPMG LLP
Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.
- directorsDaniel Curran, M.D.; Rekha Hemrajani; Chris Takimoto, M.D., Ph.D., F.A.C.P.
Class II director nominees elected to serve until the 2029 annual meeting.
